ABSTRACT
Approval Date: 1998 for treatment of Crohn’s disease, 1999 for reduction of signs and symptoms of rheumatoid arthritis, 2000 for inhibition of progression of structural damage in rheumatoid arthritis (U.S.); 1999 for treatment of Crohn’s disease, 2000 for treatment of rheumatoid arthritis (E.U.)
Therapeutic Indications:
Remicade is indicated in the treatment of severe, active Crohn’s disease and fistulizing Crohn’s disease in patients who have not responded to conventional therapies. It is indicated for the reduction of signs and symptoms of rheumatoid arthritis as well as the inhibition of progression of structural damage in patients who have not responded to other drugs, including methotrexate.
